IBS: A Functional Nutritionist's Guide to Root Causes, Testing and Treatment
Updated: Aug 29
Irritable bowel syndrome is one of the most common — and most misunderstood — digestive conditions I see in clinical practice. It affects an estimated 10 to 15 percent of the global population, yet the majority of people living with it have never received a clear explanation of what is actually driving their symptoms. As a functional nutritionist specialising in gut health, I work with men and women who have often spent years managing bloating, unpredictable bowel habits, pain, and fatigue without lasting relief.
In this article, I want to offer something different from the standard IBS handout: a clear, research-grounded explanation of what IBS is, what the current evidence tells us about its root causes, how functional testing can identify what conventional investigation misses, and what a truly personalised approach to treatment looks like.
What IBS Actually Is — and What It Is Not
Irritable bowel syndrome is classified as a disorder of gut-brain interaction (DGBI) — a term that replaced the older label "functional gastrointestinal disorder" in the Rome IV criteria. The term acknowledges what the research has consistently shown: IBS is not a structural disease, but it is also not a psychological one. It is a complex interplay of gut physiology, microbial environment, immune function, nervous system regulation, and brain-gut signalling — all of which are measurable, and all of which are addressable.
The diagnosis of IBS is currently made using the Rome IV criteria: recurrent abdominal pain at least one day per week in the last three months, associated with two or more of the following — change in stool frequency, change in stool form, or improvement with defecation. There are no biomarkers. No blood test confirms it. No imaging identifies it. It is a clinical diagnosis by exclusion — which means by the time someone receives it, the investigation has stopped, not started.
IBS is classified into four subtypes based on predominant bowel habit:
IBS-D (diarrhoea-predominant): frequent loose stools, urgency, incomplete evacuation
IBS-C (constipation-predominant): infrequent, hard stools, straining, bloating
IBS-M (mixed): alternating diarrhoea and constipation
IBS-U (unclassified): symptoms that do not clearly fit the above
Understanding which subtype you have matters clinically — not because each subtype has a different drug, but because each pattern points to different underlying mechanisms that require different investigation priorities.
Why IBS Keeps Being Mismanaged
A 2025 paper published in PMC titled It Is Time for a New IBS Paradigm makes the case plainly: there is now overwhelming evidence that the root cause of IBS in a significant proportion of patients originates from bacterial dysbiosis, yet diagnosis and treatment are not routinely offered. Instead, patients are offered palliative measures. The authors draw a parallel with H. pylori and peptic ulcer disease — a condition treated for decades as a stress-related somatoform illness until its bacterial origin was identified, after which targeted treatment became curative.
The same paradigm shift is overdue for IBS. The low FODMAP diet — the most commonly recommended dietary intervention — is a symptom management tool, not a treatment. It reduces fermentable substrate available to gut bacteria and temporarily reduces gas and bloating. It does not address why the bacteria are behaving the way they are, why the gut lining is hyperpermeable, why the gut-brain axis is dysregulated, or why visceral hypersensitivity has developed. In my clinical practice as a functional nutritionist, the patients who arrive having followed a low FODMAP diet for months or years are frequently more food-restricted than when they started, with symptoms that have adapted and continue.
The question is never just "what are you eating?" It is always "what is happening in your gut, and why?"
The Root Causes of IBS — What the Research Shows
IBS does not have a single cause. It is a clinical endpoint that multiple pathophysiological pathways can produce. Identifying which pathway — or combination of pathways — is operating in an individual is the clinical task that a functional nutritionist is equipped to address.
Microbial Dysbiosis and Bacterial Overgrowth
The evidence for microbial dysbiosis as a central driver of IBS is now substantial. A 2024 systematic review with meta-analysis published in Digestive Diseases and Sciences confirmed significantly elevated pro-inflammatory markers — including IL-6 and TNF-α — alongside altered gut microbial composition in IBS patients compared to healthy controls. The microbiome in IBS is consistently characterised by reductions in beneficial Bifidobacterium and Faecalibacterium prausnitzii species, and increases in pro-inflammatory gram-negative bacteria.
The relationship between IBS and SIBO (Small Intestinal Bacterial Overgrowth) is particularly clinically significant. Research published in Gut Microbiota for Health from Digestive Disease Week 2025 noted that the prevalence of SIBO in patients with IBS ranges from 4 to 78 percent depending on the testing method and population studied. In clinical practice, methane-dominant SIBO is particularly associated with IBS-C, while hydrogen-dominant SIBO is more commonly seen in IBS-D. Treating SIBO without recognising its role in IBS produces incomplete results — treating IBS without investigating SIBO misses one of its most common drivers.
Post-Infectious IBS (PI-IBS)
One of the most clinically significant — and consistently underdiagnosed — subtypes is post-infectious IBS. A 2024 systematic review and meta-analysis published in Gut confirmed that following acute gastroenteritis, approximately 10 percent of patients develop IBS that persists long after the infection has resolved.
The mechanism is well characterised: acute infection with organisms such as Campylobacter jejuni, Salmonella spp., or Escherichia coli triggers a marked shift in the gut microbiota, disrupts the intestinal barrier, alters neuromuscular function, and induces persistent low-grade mucosal inflammation. These changes affect gut-brain axis signalling and can produce visceral hypersensitivity that continues indefinitely in susceptible individuals.
Clinically, if your gut problems began or significantly worsened following a stomach bug, a bout of food poisoning, a period of traveller's diarrhoea, or a COVID-19 infection, post-infectious IBS should be a primary consideration. It has specific clinical implications for how the gut microbiome is investigated and supported.
Increased Intestinal Permeability
Intestinal barrier dysfunction is consistently documented in IBS, particularly the diarrhoea-predominant subtype. A 2024 review published in Immunology (Wiley) reported that barrier dysfunction was observed in 37 to 62 percent of IBS-D patients and 4 to 25 percent of IBS-C patients, with impaired intestinal barrier function strongly associated with abdominal pain and altered bowel habits.
When tight junctions — the protein structures that seal the gaps between intestinal cells — are compromised, bacterial endotoxins such as LPS translocate into systemic circulation, driving immune activation and the low-grade systemic inflammation that produces many of the non-digestive symptoms people with IBS experience: fatigue, brain fog, joint pain, and skin reactivity.
This is the mechanism by which IBS produces symptoms that appear entirely unrelated to the gut. It also explains why a significant number of people with IBS test positive for elevated zonulin — the primary regulator of intestinal permeability — and why addressing barrier function is a core component of any effective treatment protocol.
Visceral Hypersensitivity and Gut-Brain Axis Dysregulation
People with IBS experience pain and discomfort at levels of gut distension that would produce no symptoms in someone without IBS. This is visceral hypersensitivity — a lowered pain threshold in the gut that is driven by changes in the enteric nervous system and central sensitisation.
The gut-brain axis — the bidirectional communication network connecting the enteric nervous system, the vagus nerve, and the central nervous system — is dysregulated in IBS. Chronic stress, trauma, anxiety, and poor sleep all activate the hypothalamic-pituitary-adrenal (HPA) axis, which directly modulates gut motility, intestinal permeability, and visceral pain perception. Emerging 2025 research published in Gastroenterology has identified NMDA receptor hyperfunction — associated with microbial dysbiosis — as a mechanism underlying visceral hypersensitivity in post-infectious IBS, further establishing the microbiome-gut-brain axis as a central target for intervention.
This does not mean IBS is psychological. It means the gut and the brain are in continuous bidirectional communication, and dysregulation in either direction produces measurable physiological consequences in the other.
Low Stomach Acid and Impaired Digestive Function
Adequate gastric acid production is a fundamental requirement for normal digestion, nutrient absorption, and the prevention of bacterial overgrowth in the upper digestive tract. When stomach acid is chronically low — through long-term proton pump inhibitor (PPI) use, H. pylori infection, chronic stress, or age-related decline — the upper gut becomes vulnerable to bacterial colonisation, protein digestion is impaired, and nutrient deficiencies develop that compound the clinical picture.
In clinical practice, hypochlorhydria is a frequently overlooked contributor to IBS, particularly in patients who have been prescribed PPIs without a clear ongoing indication and who notice that their symptoms worsened after starting the medication.
Food Intolerances and Immune-Mediated Reactivity
Not all food reactions in IBS are the same, and distinguishing between them matters clinically. IgE-mediated food allergy, non-coeliac gluten sensitivity, FODMAPs sensitivity, histamine intolerance, and salicylate reactivity all produce overlapping symptoms and require different investigation and management approaches.
A significant proportion of people with IBS-D have non-coeliac gluten sensitivity — an immune-mediated reaction to wheat proteins that produces intestinal permeability and inflammation without the autoimmune component of coeliac disease. Histamine intolerance, driven by reduced DAO enzyme activity — often itself a consequence of dysbiosis and intestinal permeability — is another frequently missed layer that produces flushing, headaches, skin reactivity, and worsening gut symptoms after high-histamine foods.
Symptoms Beyond the Gut
IBS is rarely a condition confined to the digestive system. The systemic consequences of microbial dysbiosis, intestinal permeability, and gut-brain axis dysregulation produce symptoms across multiple body systems that are frequently investigated and managed as separate conditions, with no one connecting them to the gut.
Common extra-intestinal symptoms associated with IBS include:
Chronic fatigue disproportionate to lifestyle and not restored by sleep
Brain fog and difficulty concentrating — driven by LPS-mediated neuroinflammation and gut-brain axis dysregulation
Anxiety and mood disturbance — the gut produces approximately 95 percent of the body's serotonin; dysbiosis directly affects neurotransmitter production
Skin conditions — eczema, rosacea, and acne have all been associated with gut dysbiosis and increased intestinal permeability
Joint pain and inflammation without an identified rheumatological cause
Hormonal dysregulation — the estrobolome, the subset of gut bacteria responsible for oestrogen metabolism, is directly compromised by dysbiosis, with measurable effects on circulating hormone levels
Nutrient deficiencies — malabsorption driven by gut inflammation and reduced digestive enzyme activity produces deficiencies in B12, iron, zinc, magnesium, and vitamin D that worsen fatigue, mood, and immune function
If you are managing IBS alongside several of these symptoms and have been told they are unrelated, they are almost certainly not.
How a Functional Nutritionist Investigates IBS
The fundamental difference between a functional nutritionist's assessment of IBS and a conventional gastroenterology work-up is what gets investigated once structural disease has been excluded.
Conventional medicine excludes coeliac disease, inflammatory bowel disease, colorectal cancer, and a small number of other conditions. When these are ruled out and symptoms remain, the label IBS is applied and management becomes symptomatic.
A functional nutritionist begins where that work-up ends. The question is no longer "what disease do you have?" but "what physiological mechanisms are producing your symptoms, and which are the primary drivers in your specific case?"
Comprehensive Stool Analysis
A detailed stool analysis — such as the GI-MAP or equivalent — provides a detailed picture of the gut microbiome, including dysbiosis patterns, the presence of pathogenic bacteria, markers of gut inflammation (calprotectin, zonulin), secretory IgA levels (the gut's first-line immune defence), and markers of digestive function. This is the foundational investigation for IBS in a functional nutrition context and frequently identifies the primary driver of symptoms that has not been identified by any previous investigation.
Breath Testing for SIBO
Hydrogen and methane breath tests measure the gas produced by bacteria fermenting a substrate in the small intestine. Elevated hydrogen suggests bacterial overgrowth; elevated methane suggests intestinal methanogen overgrowth (IMO) — a distinct entity that produces constipation and is caused by archaea rather than bacteria, requiring a specific treatment approach. Identifying whether SIBO is present, and which gas type predominates, directly informs the treatment protocol.
Intestinal Permeability Markers
Serum or stool zonulin, LPS-binding protein, and urinary lactulose-mannitol ratio testing provide objective evidence of barrier dysfunction. These markers confirm whether translocation of bacterial endotoxins is contributing to the systemic symptom picture and guide the priority and sequencing of interventions.
Organic Acids and Nutrient Assessment
Organic acids testing identifies metabolic markers of dysbiosis, mitochondrial function, and nutrient status. Combined with a targeted nutrient panel, this provides a clear picture of the deficiencies that need correcting as part of restoring optimal gut and systemic function.
Food Sensitivity and Immune Testing
Where clinically indicated, IgG food sensitivity testing, coeliac antibody panels, and histamine-related enzyme activity testing help identify immune-mediated reactivity patterns that are maintaining the cycle of gut inflammation.
The Functional Nutritionist's Treatment Framework for IBS
Treatment for IBS in a functional nutrition context is not a protocol — it is a process, and it is always personalised to what the individual's clinical history and test results reveal. That said, the approach follows a consistent logic.
Step 1: Identify and Address the Primary Driver
The most important step — and the one most consistently skipped in self-directed treatment attempts — is identifying which mechanism is the primary driver of symptoms in this individual. SIBO requires a different intervention than post-infectious dysbiosis. Histamine intolerance requires a different approach than non-coeliac gluten sensitivity. Visceral hypersensitivity driven by gut-brain axis dysregulation requires specific nervous system support that dietary change alone will not provide.
Without identifying the primary driver, interventions are applied generically, which is why so many people with IBS cycle through diets and supplements without lasting relief. This is where working with a functional nutritionist makes a measurable difference.
Step 2: Restore Microbial Balance
Addressing dysbiosis is central to any effective IBS protocol. The approach — whether antimicrobial, probiotic, prebiotic, dietary, or a combination — is determined by what the stool analysis and breath testing reveal. The 2024 management review published in Translational Gastroenterology and Hepatology confirmed that both dietary interventions and microbiome-targeted therapies produce clinically meaningful improvements in IBS — but that the response is highly individual and dependent on the underlying microbial pattern.
Step 3: Restore Intestinal Barrier Integrity
Where permeability is confirmed, barrier restoration is a structured process that involves removing ongoing drivers of barrier disruption and providing the specific nutritional support that intestinal epithelial cells require. The specific interventions are always selected based on the individual's test results, clinical history, and any relevant medication or nutrient interactions — this is not a generic list.
Step 4: Support the Gut-Brain Axis
For individuals in whom gut-brain dysregulation is a significant component, this axis requires direct support. This may involve stress physiology work, vagal tone support, sleep optimisation, and nervous system regulation strategies that are integrated with the dietary and microbiome-focused elements of the protocol.
Step 5: Reintroduce, Retest, and Refine
As gut function improves, a systematic reintroduction of any eliminated foods allows for accurate identification of true food sensitivities versus permeability-driven or dysbiosis-driven reactivity. Many people find that foods they had been reacting to for years — that appeared to be fixed intolerances — resolve as gut integrity and microbial balance are restored. Retesting objective markers at 3 to 6 months provides evidence of progress and guides decisions about continuing or adjusting the approach.
Why Conventional Treatment Alone Produces Limited Results
Antispasmodics, laxatives, anti-diarrhoeals, and low-dose antidepressants reduce symptoms in some people with IBS. They do not restore microbial balance. They do not repair intestinal barrier function. They do not resolve SIBO. They do not address the gut-brain dysregulation that drives visceral hypersensitivity. And they do not identify or correct the nutrient deficiencies that compound the picture.
This is not a criticism of the clinicians who prescribe them — it is a reflection of what conventional gastroenterology is currently designed to investigate and manage. The tools exist to go significantly further. A functional nutritionist uses them.
When to Seek a Functional Nutrition Assessment
Consider working with a functional nutritionist if:
Your symptoms have not responded meaningfully to dietary changes, including low FODMAP
You have been managing IBS for more than 6 months without a clear improvement trajectory
Your symptoms began or significantly worsened after a gastrointestinal infection
You are experiencing significant non-digestive symptoms alongside your gut symptoms — fatigue, brain fog, skin issues, joint pain or mood disturbance
You have been prescribed PPIs or antibiotics repeatedly without investigating why your symptoms recurred
You want to understand what is actually driving your symptoms, not just manage them
Frequently Asked Questions
Is IBS a real condition or is it just stress?
IBS is a genuine physiological condition — not a stress response or an imaginary one. The Rome IV criteria provide a clinical framework for its diagnosis, and the research documenting its underlying mechanisms — microbial dysbiosis, intestinal permeability, visceral hypersensitivity, gut-brain axis dysregulation — is extensive and published in the highest-quality gastroenterology journals. Stress is one of several factors that exacerbates IBS through well-documented neuroimmune mechanisms, but it is rarely the primary cause and never the complete explanation.
Can IBS be cured?
IBS as a label does not have a cure because it is not a single disease. What it describes — a pattern of gut symptoms driven by specific physiological mechanisms — is in most cases very significantly improvable when those mechanisms are identified and addressed. Many of my clients who have been told they will "just have to manage" their IBS reach a point where their symptoms are minimal or absent, and their food tolerance is substantially restored. The degree of resolution depends on the underlying drivers and how long they have been operating.
Is the low FODMAP diet a treatment for IBS?
The low FODMAP diet is a symptom management tool, not a treatment. It works by reducing fermentable substrate available to gut bacteria, which reduces gas production and temporarily reduces bloating and pain. It does not address why the bacteria are behaving the way they are, whether SIBO is present, or why the gut lining is permeable. Long-term low FODMAP dieting without addressing underlying drivers typically results in increasing food restriction over time, reduced microbial diversity, and symptoms that return when any restricted food is reintroduced. It is a useful short-term tool as part of a broader protocol — not a long-term solution.
How do I know if I have SIBO alongside IBS?
Hydrogen and methane breath testing is the primary investigation for SIBO. Clinical indicators that SIBO may be present include: bloating that is consistently worse as the day progresses, particularly after meals; constipation that does not respond to fibre or hydration changes; a history that began or worsened after an acute gut infection; previous antibiotic use without gut recovery; or symptoms that briefly improved on antibiotics and then returned. These are clinical patterns — a breath test provides objective confirmation.
Why do I react to so many foods — is that normal with IBS?
Multiplying food intolerances are a clinical signal, not simply a feature of IBS. In most cases, they reflect intestinal permeability — the barrier is allowing incompletely digested food proteins to contact immune cells that then mount a response. As more foods enter this pattern, the list of reactive foods grows. This is not a fixed state. As gut integrity is restored and microbial balance improves, many people find their food tolerance expands significantly. The goal of a functional nutritionist working with IBS is not an ever-shorter list of safe foods — it is a gut that can handle a varied diet again.
How long does it take to see improvement?
This is highly individual and depends on the duration of symptoms, the severity of underlying dysbiosis and permeability, and the consistency of the protocol. In my clinical experience as a functional nutritionist, most people begin to notice meaningful symptomatic improvement within 6 to 12 weeks of a personalised protocol. Objective marker improvement — as measured by stool testing and permeability retesting — typically takes 3 to 6 months. For those with longstanding IBS and significant post-infectious components, full resolution may take longer, but the improvement trajectory is typically clear within the first 3 months.
Work With a Functional Nutritionist for IBS
I work with men and women internationally through online consultations as a functional nutritionist, using comprehensive case history, targeted functional testing, and personalised protocols built around what your results and your clinical picture actually show.
If you have been living with IBS and have not found lasting improvement through conventional management or self-directed dietary approaches, the starting point is a consultation where we map your full history, identify which investigations are most relevant for your case, and build a protocol that addresses the specific mechanisms operating for you.
IBS is not something you have to simply manage. Understanding what is driving it changes everything.
Scientific References
Black CJ, Ford AC. (2024). Irritable bowel syndrome: a clinical review. Lancet, 403(10428), 1680–1692.
Porcari S, Ingrosso MR, Maida M, et al. (2024). Prevalence of irritable bowel syndrome and functional dyspepsia after acute gastroenteritis: systematic review and meta-analysis. Gut, 73(9), 1431–1440. doi:10.1136/gutjnl-2023-331835
Chen L, et al. (2024). Gut microbiota and intestinal immunity — a crosstalk in irritable bowel syndrome. Immunology (Wiley). doi:10.1111/imm.13749
Goodoory VC, et al. (2024). Effect of brain-gut behavioural treatments on abdominal pain in irritable bowel syndrome: systematic review and network meta-analysis. Gastroenterology, 167(5), 934–943.
Horowitz A, et al. (2024). Critical appraisal of the SIBO hypothesis and breath testing: a clinical practice update. Neurogastroenterology & Motility, 36(6), e14817.
Vanhoutvin SALW, et al. (2024). The interplay between immunological status and gut microbial dysbiosis in IBS. Digestive Diseases and Sciences. doi:10.1007/s10620-025-09360-w
Du L, et al. (2025). Microbial dysbiosis-associated NMDAR hyperfunction in post-infectious IBS with visceral hypersensitivity. Gastroenterology. doi:10.1093/gastro/goaf065
Weaver KR, et al. (2024). Treatment of functional bowel disorders in an integrative medicine clinic. JGH Open. PMC10805498.
El-Salhy M, et al. (2023). Irritable bowel syndrome: The functional medicine approach. Annals of Innovation in Medicine, 1(1). doi:10.59652/aim.v1i1.32
Berumen A, Edwinson AL, Grover M. (2021). Post-infection irritable bowel syndrome. Gastroenterology Clinics of North America, 50(2), 445–461.
Comments